SCHEMBL403623

SCHEMBL403623

Cc1ccc(C(=O)Nc2ccc(CCCC(=O)Oc3ccc(C(=O)OCc4cccnc4)cc3)cc2C(=O)N(C)C)c(-c2ccc(C(F)(F)F)cc2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 2/20 0.39
NTRK2 Q16620 1/20 0.39
HDAC1 Q13547 11/20 0.36
HIF1A Q16665 1/20 0.36
EPAS1 Q99814 1/20 0.36
HDAC3 O15379 5/20 0.36
HDAC2 Q92769 5/20 0.36
HDAC8 Q9BY41 4/20 0.36
HDAC4 P56524 3/20 0.36
HDAC7 Q8WUI4 3/20 0.36
HDAC10 Q969S8 3/20 0.36
HDAC11 Q96DB2 3/20 0.36
HDAC6 Q9UBN7 3/20 0.36
HDAC9 Q9UKV0 3/20 0.36
HDAC5 Q9UQL6 3/20 0.36
KDM1A O60341 1/20 0.35
BTK Q06187 1/20 0.34
PTAFR P25105 1/20 0.34
PDK1 Q15118 1/20 0.34
GPR132 Q9UNW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL401089 0.93 NTRK1 (0.41) NTRK1NTRK2BTK
SCHEMBL402266 0.91 NTRK1 (0.43) NTRK1NTRK2KCNH2
SCHEMBL402484 0.90 NTRK1 (0.40) NTRK1NTRK2KCNH2
SCHEMBL10205546 0.89 NTRK1 (0.42) NTRK1NTRK2KCNH2
SCHEMBL403014 0.89 MTTP (0.41) HDAC1HIF1AEPAS1HDAC3HDAC2
SCHEMBL5318000 0.87 NTRK1 (0.43) NTRK1NTRK2KCNH2
SCHEMBL401283 0.87 NTRK1 (0.40) NTRK1NTRK2KCNH2
Sulfuric Acid SCHEMBL402780 0.85 NTRK1 (0.39) NTRK1NTRK2KCNH2
SCHEMBL401345 0.83 NTRK1 (0.40) NTRK1NTRK2HDAC1HDAC3HDAC2
SCHEMBL402082 0.83 KCNH2 (0.38) NTRK1BTKKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1803452-A1 ESTER DERIVATIVE AND PHARMACEUTICAL USE THEREOF Japan Tobacco, Inc. (JP) 2007-07-04 EP claimed
US-20060089392-A1 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2006-04-27 US claimed
US-8101774-B2 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2012-01-24 US disclosed
US-8101774-B2 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2012-01-24 US disclosed
US-8101774-B2 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2012-01-24 US disclosed
EP-1803452-A1 ESTER DERIVATIVE AND PHARMACEUTICAL USE THEREOF Japan Tobacco, Inc. (JP) 2007-07-04 EP disclosed
US-20060089392-A1 Ester derivatives and medicinal use thereof JAPAN TOBACCO INC. (JP) 2006-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089392-A1 Ester derivatives and medicinal use thereof MTTP, CETP, LIPA NTRK1 3420/4885NTRK2 2775/4885HDAC1 307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.